Literature DB >> 15798917

Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.

Emilia Barcia1, Rodrigo Reyes, Maria Luz Azuara, Yolanda Sánchez, Sofía Negro.   

Abstract

The aim of this study was to determine the compatibility and stability of morphine hydrochloride and hyoscine-N-butyl bromide combined in solution at three different concentrations and stored in polypropylene syringes at 4 degrees C and 25 degrees C over a period of 15 days. The doses assayed were 20, 60 and 120 mg/day for morphine hydrochloride and 40, 60 and 80 mg/day for hyoscine-N-butyl bromide. These dose ranges were chosen according to daily practice. At both temperatures, all mixtures can be considered as physically compatible since no evidence of incompatibility-that is precipitation, turbidity, colour change or opacity and gas production-were observed. After 15 days of storage, the percentages of hyoscine-N-butyl bromide remaining in the drug mixtures tested ranged between 96.07% and 92.23%. At the end of the study, the percentages of morphine hydrochloride remaining in the drug mixtures were 100% at both temperatures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15798917     DOI: 10.1007/s00520-004-0719-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  19 in total

Review 1.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

2.  Determination of compatibility and stability of drugs used in palliative care.

Authors:  D Schrijvers; C Tai-Apin; M C De Smet; P Cornil; J B Vermorken; P Bruyneel
Journal:  J Clin Pharm Ther       Date:  1998-08       Impact factor: 2.512

3.  Administration of drugs by infusion pumps in palliative medicine.

Authors:  A B Thorsen; N S Yung; A C Leung
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

4.  Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.

Authors:  C Ripamonti; S Mercadante; L Groff; E Zecca; F De Conno; A Casuccio
Journal:  J Pain Symptom Manage       Date:  2000-01       Impact factor: 3.612

5.  Oral morphine for relief of chronic pain from cancer.

Authors:  T D Walsh; C M Saunders
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

6.  A new method to obtain and present complete information on the compatibility: study of its validity for eight binary mixtures of morphine with drugs frequently used in palliative care.

Authors:  An Vermeire; Jean Paul Remon; Dirk Schrijvers; Peter Demeulenaere
Journal:  Palliat Med       Date:  2002-09       Impact factor: 4.762

7.  Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.

Authors:  Sofía Negro; María Luz Azuara; Yolanda Sánchez; Rodrigo Reyes; Emilia Barcia
Journal:  Support Care Cancer       Date:  2002-01       Impact factor: 3.603

8.  Compatibility and stability of ternary admixtures of morphine with haloperidol or midazolam and dexamethasone or methylprednisolone.

Authors:  A Vermeire; J P Remon
Journal:  Int J Pharm       Date:  1999-01-15       Impact factor: 5.875

9.  Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.

Authors:  Emilia Barcia; Rodrigo Reyes; María Luz Azuara; Yolanda Sánchez; Sofía Negro
Journal:  Support Care Cancer       Date:  2003-01-10       Impact factor: 3.603

10.  Subcutaneous infusions for control of cancer symptoms.

Authors:  P Storey; H H Hill; R H St Louis; E E Tarver
Journal:  J Pain Symptom Manage       Date:  1990-02       Impact factor: 3.612

View more
  2 in total

1.  Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.

Authors:  María Espinosa-Bosch; Fuensanta Sanchez-Rojas; Catalina Bosch-Ojeda
Journal:  Eur J Hosp Pharm       Date:  2018-01-27

Review 2.  The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review.

Authors:  James Baker; Andrew Dickman; Stephen Mason; John Ellershaw
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.